Osteoporosis in children and adolescents etiology and management

被引:66
作者
Baroncelli G.I. [1 ]
Bertelloni S. [1 ]
Sodini F. [1 ]
Saggese G. [1 ,2 ]
机构
[1] Department of Pediatrics, University of Pisa, Pisa
[2] Department of Pediatrics, University of Pisa, Pisa, I-56126
关键词
Bone Mineral Density; Osteoporosis; Bone Mass; Juvenile Idiopathic Arthritis; Osteogenesis Imperfecta;
D O I
10.2165/00148581-200507050-00003
中图分类号
学科分类号
摘要
Bone mass increases progressively during childhood, but mainly during adolescence when approximately 40% of total bone mass is accumulated. Peak bone mass is reached in late adolescence, and is a well recognised risk factor for osteoporosis later in life. Thus, increasing peak bone mass can prevent osteoporosis. The critical interpretation of bone mass measurements is a crucial factor for the diagnosis of osteopenia/osteoporosis in children and adolescents. To date, there are insufficient data to formally define osteopenia/osteoporosis in this patient group, and the guidelines used for adult patients are not applicable. In males and females aged <20 years the terminology 'low bone density for chronologic age' may be used if the Z-score is less than -2. For children and adolescents, this terminology is more appropriate than osteopenia/osteoporosis. Moreover, the T-score should not be used in children and adolescents. Many disorders, by various mechanisms, may affect the acquisition of bone mass during childhood and adolescence. Indeed, the number of disorders that have been identified as affecting bone mass in this age group is increasing as a consequence of the wide use of bone mass measurements. The increased survival of children and adolescents with chronic diseases or malignancies, as well as the use of some treatment regimens has resulted in an increase in the incidence of reduced bone mass in this age group. Experience in treating the various disorders associated with osteoporosis in childhood is limited at present. The first approach to osteoporosis management in children and adolescents should be aimed at treating the underlying disease. The use of bisphosphonates in children and adolescents with osteoporosis is increasing and their positive effect in improving bone mineral density is encouraging. Osteoporosis prevention is a key factor and it should begin in childhood. Pediatricians should have a fundamental role in the prevention of osteoporosis, suggesting strategies to achieve an optimal peak bone mass. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码:295 / 323
页数:28
相关论文
共 192 条
[91]  
Riggs B.L., Khosla S., Melton L.J., Sex steroids and the construction and conservation of adult skeleton, Endocr Rev, 23, pp. 279-302, (2002)
[92]  
Marcus R., Leary D., Schneider D.L., Et al., The contribution of testosterone to skeletal development and maintenance: Lessons from the androgen insensitivity syndrome, J Clin Endocrinol Metab, 85, pp. 1032-1037, (2000)
[93]  
Khosla S., Melton L.J., Riggs B.L., Estrogen and the male skeleton, J Clin Endocrinol Metab, 87, pp. 1443-1450, (2002)
[94]  
Cowell C.T., Woodhead H., Brody J., Bone markers and bone mineral density during growth hormone treatment in children with growth hormone deficiency, Horm Res, 54, 1 SUPPL., pp. 44-51, (2000)
[95]  
Baroncelli G.I., Bertelloni S., Ceccarelli C., Et al., Dynamics of bone turnover in children with GH deficiency treated with GH until final height, Eur J Endocrinol, 142, pp. 549-556, (2000)
[96]  
Baroncelli G.I., Bertelloni S., Sodini F., Et al., Acquisition of bone mass in normal subjects and in patients with growth hormone deficiency, J Pediatr Endocrinol Metab, 16, pp. 327-335, (2003)
[97]  
Van Der Sluis I.M., Boot A.M., Hop W.C., Et al., Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: A 6-year follow-up study, Horm Res, 58, pp. 207-214, (2002)
[98]  
Kandemir N., Gonc E.N., Yordam N., Responses of bone turnover markers and bone mineral density to growth hormone therapy in children with isolated growth hormone deficiency and multiple pituitary hormone deficiencies, J Pediatr Endocrinol Metab, 15, 6, pp. 809-816, (2002)
[99]  
Baroncelli G.I., Bertelloni S., Sodini F., Et al., Lumbar bone mineral density at final height and prevalence of fractures in treated children with growth hormone deficiency, J Clin Endocrinol Metab, 87, pp. 3624-3631, (2002)
[100]  
Faber J., Galloe A.M., Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis, Eur J Endocrinol, 130, pp. 350-356, (1994)